Metabolic Syndrome Clinical Trial
Official title:
Double Blind, Randomized, Placebo-controlled Study of Safety and Tolerability of Treamid in Rising Doses at Single and Then Multiple Oral Administration in Healthy Volunteers
Verified date | June 2020 |
Source | PHARMENTERPRISES LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of Treamid after single and repeated oral administration in healthy volunteers. The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break. The primary objective of the study was to evaluate the safety and tolerability profile of Treamid after single and multiple administration based on the frequency and severity of adverse events and changes in vital signs, laboratory results, electrocardiography and results of the physical examination. The secondary objective of the study was to assess pharmacokinetics of active pharmaceutical substance of Treamid.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 21, 2016 |
Est. primary completion date | November 21, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Non-smoking male at the age from 18 to 50 years old (inclusive); 2. Verified diagnosis "healthy" according to standard clinical, laboratory and instrumental methods of examination; 3. Body mass index from 18.5 to 30 kg/m2 (inclusive); 4. Agreement to use adequate contraception methods during the study and 3 months after its completion (condoms with spermicide); 5. Signed patient explanation sheet and informed consent for participation in the study. Exclusion Criteria: 1. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems and diseases of the gastrointestinal tract, liver, kidneys, blood; 2. Laboratory deviations from normal values at screening (the deviations will not include single violations of reference ranges of laboratory parameter if they are not accompanied with any clinical symptoms, do not require additional examination or treatment and are not confirmed by values of related laboratory parameters); 3. Regular administration of drugs in less than 2 weeks before starting the study; administration of drugs effecting on hemodynamics, liver function, and others. (barbiturates, omeprazole, cimetidine, etc.) in less than 30 days before starting the study; 4. Antibodies to HIV and hepatitis C, hepatitis B surface antigen, positive test for syphilis; 5. Unstable sleep architecture (e.g. night work, sleep disorders, insomnia, recently returned from another time zone, etc.); 6. Signs of alcohol or drug addiction; taking alcohol or narcotic drugs during 4 days prior to screening (taking more than 10 units of alcohol per week (1 unit of alcohol is equivalent ½ liters of beer, 200 ml of wine or 50 ml of hard alcoholic beverages); 7. Medical history significant for allergic (including drug intolerance and food allergies); 8. Symptomatic rhinitis in past medical history during 2 years before screening (allergic rhinitis, non-allergic rhinitis or allergic coryza); 9. Blood/plasma donation (from 450 ml) in less than 2 months prior to screening; 10. Surgeries in hospital environment (except appendectomy) during 12 weeks prior to screening; 11. Participation in other clinical studies or taking other investigated drugs during 3 months prior to screening; 12. Inability to understand or comply with the protocol procedures; 13. Acute infectious diseases in less than 4 weeks prior to screening. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
PHARMENTERPRISES LLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Adverse events per treatment arm Number of Adverse events per treatment arm | Adverse events have been classified according to CTCAE ver 4.03. Adverse events will be summarized descriptively by treatment arm. Verbatim terms will be mapped to preferred terms and organ systems using the current Medical Dictionary for Regulatory Activities version. For each preferred term, frequency counts and percentages will be calculated by cohort. The nature, severity, seriousness, and relationship to study drug will be summarized for all study subjects. | Day -13 (14 days before first dose) - Day 50 | |
Secondary | Pharmacokinetics of Treamid by assessing AUC0-inf | Area under the curve "concentration of the drug-time" from the time of administration of the drug till infinity | Day 1 and Day 21 (Pre dose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 6, 8 and 12 hours post dose), Day 2 and Day 22 (24 hours post dose), Day 3 (48 hours post dose), Day 4 (72 hours post dose), Days 8 - 12 and Day 15 (Pre dose) | |
Secondary | Pharmacokinetics of Treamid by assessing Cmax | Maximum plasma concentration | Day 1 and Day 21 (Pre dose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 6, 8 and 12 hours post dose), Day 2 and Day 22 (24 hours post dose), Day 3 (48 hours post dose), Day 4 (72 hours post dose), Days 8 - 12 and Day 15 (Pre dose) | |
Secondary | Pharmacokinetics of Treamid by assessing AUC0-t | Area under the curve "concentration of the drug-time" from the time of administration of the drug till the time (t) the last blood sampling | Day 1 and Day 21 (Pre dose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 6, 8 and 12 hours post dose), Day 2 and Day 22 (24 hours post dose), Day 3 (48 hours post dose), Day 4 (72 hours post dose), Days 8 - 12 and Day 15 (Pre dose) | |
Secondary | Pharmacokinetics of Treamid by assessing Tmax | Time to maximum drug concentration in the blood plasma administration | Day 1 and Day 21 (Pre dose, 15 minutes, 30 minutes, 1, 1.5, 2, 3, 6, 8 and 12 hours post dose), Day 2 and Day 22 (24 hours post dose), Day 3 (48 hours post dose), Day 4 (72 hours post dose), Days 8 - 12 and Day 15 (Pre dose) | |
Secondary | Pharmacokinetics of Treamid by assessing T1/2 | Terminal elimination half-life | Day 1 and Day 21 (Pre dose, 15 minites, 30 minutes, 1, 1.5, 2, 3, 6, 8 and 12 hours post dose), Day 2 and Day 22 (24 hours post dose), Day 3 (48 hours post dose), Day 4 (72 hours post dose), Days 8 - 12 and Day 15 (Pre dose) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04635202 -
Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome
|
N/A | |
Completed |
NCT05343858 -
Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome
|
N/A | |
Completed |
NCT04053686 -
An Intervention to Reduce Prolonged Sitting in Police Staff
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Recruiting |
NCT05040958 -
Carotid Atherosclerotic Plaque Load and Neck Circumference
|
||
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Active, not recruiting |
NCT03613740 -
Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
|
Phase 2 | |
Completed |
NCT04498455 -
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
|
Phase 4 | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04509206 -
Virtual Teaching Kitchen
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A |